Dr Meredith McKean speaks to ecancer about her highlights from ASCO 2024 in the field of melanoma.
She highlights the NADINA study which showed a significant improvement in event-free survival with ipilimumab plus nivolumab for patients with resectable stage III melanoma.
Dr McKean also covers RELATIVITY-048, which showed a high response rate for nivolumab, relatlimab, and ipilimumab with better toxicity levels than just ipilimumab plus nivolumab.